Original Article | Published:

Immune effect and safety evaluation of vaccine prepared by dendritic cells modified by rAAV-carrying BCSG1 gene

Gene Therapy volume 23, pages 839845 (2016) | Download Citation

Abstract

The immune effect and safety evaluation of rAAV (recombinant adeno-associated virus)-containing Bcsg1 (breast cancer-specific gene 1) (rAAV/Bcsg1)-transfected DC (dendritic cell) (rAAV/Bcsg1-DC) vaccine in immunotherapy for (BCSG1) (+) BC was assessed. Immune effect of cytotoxic T lymphocytes (CTLs) on Bcsg1 (+) BC cells, and rAAV gene residuals in mature CTL cells and culture medium were determined. Nude mouse xenograft tumor model was established to assess the inhibition effects of DC-activated CTLs on tumor growth. DC cell surface markers were highly expressed in rAAV/Bcsg1 group and lysate-DC group, and rAAV/Bcsg1-DC-CTL showed stronger cytotoxic activity targeting Bcsg1 (+) BC cells. The rAAV/Bcsg1-DC vaccine-treated groups showed lower mean tumor weight, higher tumor inhibition rates and slower tumor growth. rAAV/Bcsg1-DC can induce highly efficient CTL-targeting Bcsg1 antigen without rAAV gene residuals.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Breast cancer in China. Lancet Oncol 2014; 15: e279–e289.

  2. 2.

    , , , , , . Report of cancer incidence and mortality in China, 2010. Ann Transl Med 2014; 2: 61.

  3. 3.

    , , , , , . Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 2008; 60: 173–183.

  4. 4.

    , . Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265–277.

  5. 5.

    , , , , , et al. Immunity to pathogens taught by specialized human dendritic cell subsets. Front Immunol 2015; 6: 527.

  6. 6.

    , , , . The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies. Immunotherapy 2015; 7: 1111–1122.

  7. 7.

    . Tumor vaccines for breast cancer. Cancer Invest 2009; 27: 361–368.

  8. 8.

    , , , , , et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother 2014; 10: 52–63.

  9. 9.

    , , , , , . Dendritic/tumor fusion cell-based vaccination against cancer. Arch Immunol Ther Exp (Warsz) 2007; 55: 281–287.

  10. 10.

    , , , , , et al. Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells. Breast Cancer Res Treat 2007; 105: 277–286.

  11. 11.

    , , , . Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 2007; 25: 2610–2619.

  12. 12.

    , , , . Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells pulsed with recombinant adeno-associated virus carrying alpha-fetoprotein gene or cancer cell lysate. Mol Med Rep 2015; 11: 3174–3180.

  13. 13.

    , , , , , et al. Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice. BMC Cancer 2012; 12: 153.

  14. 14.

    , , , , , et al. Adeno-associated virus-mediated expression of recombinant CBD-HepII polypeptide of human fibronectin inhibits metastasis of breast cancer. Breast Cancer Res Treat 2014; 143: 33–45.

  15. 15.

    , , , , , et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res 1997; 57: 759–764.

  16. 16.

    , , , , , et al. Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res 2014; 16: 204.

  17. 17.

    , . Immunotherapy for the treatment of breast cancer. Curr Oncol Rep 2015; 17: 5.

  18. 18.

    , . Cancer immunotherapy in clinical practice – the past, present, and future. Chin J Cancer 2014; 33: 445–457.

  19. 19.

    , , , , . Adeno-associated virus-mediated antiangiogenic gene therapy with thrombospondin-1 type 1 repeats and endostatin. Clin Cancer Res 2007; 13: 3968–3976.

  20. 20.

    , , , , , et al. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus. Cancer Immunol Immunother 2007; 56: 1615–1624.

  21. 21.

    . DCs: a dual bridge to protective immunity. Nat Immunol 2013; 14: 890–891.

  22. 22.

    , , , , , et al. Human dendritic cells sequentially matured with CD4(+) T cells as a secondary signal favor CTL and long-term T memory cell responses. Biol Res 2012; 45: 33–43.

  23. 23.

    , , , , , et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine 2014; 32: 938–943.

  24. 24.

    , , , , , et al. [Dendritic cells infected by recombinant adeno-associated virus with CEA gene to induce antigen-specific CTL response to CD44(+)CD24(-/low) cells from MCF-7 breast cancer cell line]. Beijing Da Xue Xue Bao 2011; 43: 173–178.

  25. 25.

    , , , , , . Increased production of IFN-gamma by natural killer cells triggered with bone marrow-derived dendritic cells cultured in the presence of retinoic acid. Eur J Pharmacol 2013; 715: 321–327.

  26. 26.

    , , , , , . Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer. Mol Ther 2013; 21: 680–687.

  27. 27.

    , , , , , et al. Immunotherapy for SV40 T/t antigen-induced breast cancer by recombinant adeno-associated virus serotype 2 carrying interleukin-15 in mice. Int J Mol Med 2012; 29: 809–814.

  28. 28.

    , , , , , . Adeno-associated virus-mediated cancer gene therapy: current status. Cancer Lett 2015; 356: 347–356.

  29. 29.

    , , , , , et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 2012; 14: 80–90.

  30. 30.

    , , , , , et al. Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients. Clin Transl Oncol 2012; 14: 675–681.

  31. 31.

    , , , . Recent advances in the development of breast cancer vaccines. Breast Cancer (Dove Med Press) 2014; 6: 159–168.

  32. 32.

    , , , , , et al. IRGM variants and susceptibility to inflammatory bowel disease in the German population. PLoS One 2013; 8: e54338.

Download references

Acknowledgements

This project was supported by Natural Science Foundation of Shandong Province (ZR2015HL063) and Medical Science Foundation of Shandong Province (2014WS0300), and we would like to acknowledge the helpful comments received from our reviewers.

Author contributions

S-FC and WZ wrote the main manuscript text, W-HW and C-HZ collected the data, JD and Y-XZ prepared all the tables, and L-LZ analyzed the data. All authors reviewed the manuscript.

Author information

Author notes

    • W-H Wang
    •  & C-H Zhou

    Co-first authors.

Affiliations

  1. Central Laboratory, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, PRC

    • W-H Wang
    • , C-H Zhou
    • , J Ding
    • , Y-X Zhang
    • , L-L Zheng
    •  & S-F Chen
  2. Surgery of Mammary Gland and Thyroid, Liaocheng People’s Hospital, Liaocheng Clinical School of Taishan Medical University, Liaocheng, PRC

    • W Zhang

Authors

  1. Search for W-H Wang in:

  2. Search for C-H Zhou in:

  3. Search for J Ding in:

  4. Search for Y-X Zhang in:

  5. Search for L-L Zheng in:

  6. Search for S-F Chen in:

  7. Search for W Zhang in:

Competing interests

The authors declare no conflict of interest.

Corresponding authors

Correspondence to S-F Chen or W Zhang.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/gt.2016.63

Further reading